Eterna Therapeutics Inc.
ERNA
We are a preclinical-stage synthetic allogeneic iMSC therapy company. iMSCs are induced pluripotent stem cell ( iPSC )-derived mesenchymal stem cells. We envision a future where cell therapies powered by synthetic iMSCs can offer new options for patients with limited treatment paths and our mission is to transform the treatment of cancer and autoimmune disease by developing scalable, affordable…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$14M
▲ +68.4% YoY
Op. Margin
–
ROIC
-254.53%
▼ -225.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▲ +56.5% YoY
Op. Cash Flow (TTM)
-$11M
▲ +55.7% YoY
Net Debt
-$5M
Net Cash Position
Cash & Equiv.
$6M
5Y CAGR: -52.2%
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with ERNA
Eterna Therapeutics (ERNA) in three numbers
Questions about Eterna Therapeutics
Is Eterna Therapeutics (ERNA) overvalued?
Eterna Therapeutics trades at 0.16 times earnings. Intrinsiqq's fair value calculator has no opening value for ERNA, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Is Eterna Therapeutics a high-quality business?
Eterna Therapeutics scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 7 checks computed from SEC filings. Its best check is net debt at -$5M, and its weakest is return on capital at -254.5%. The Quality tab shows every check against its target.
Does Eterna Therapeutics (ERNA) pay a dividend?
No. Eterna Therapeutics (ERNA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 6 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in ERNA's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ERNA
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.